Correlation Between Thyroid Nodule Size and Risk of Thyroid Cancer: A Retrospective Cohort Study at a Tertiary Care Center
Diagnostics · 15.05.2026 · 16 (10) · 1505
DOI: 10.3390/diagnostics16101505 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diagnostics, online erschienen am 15.05.2026. Verfasst von Osama Zeidan und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen 15503, Bahrain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RCSI Bahrain, Royal College of Surgeons in Ireland—Medical University of Bahrain.
Abstract (Originalsprache)
Background
Thyroid nodules are common, yet only a small proportion are malignant. The independent role of nodule size in malignancy risk remains debated, particularly after adjustment for clinical, biochemical, and sonographic features.
Methods
A retrospective cohort study was conducted on adult patients with thyroid nodules evaluated between 2018 and 2025 at a tertiary care center. Clinical, laboratory, ultrasound, cytology, and histopathology data were extracted. Thyroid-stimulating hormone (TSH), free thyroxine (free T4), and sonographic characteristics were analyzed. Univariable and multivariable logistic regression were performed. Missing ultrasound data were addressed using multiple imputation (m = 20), with pooled estimates derived using Rubin’s rules. The final multivariable model included 446 patients.
Results
A total of 446 patients were included, of whom 91 (20.4%) had thyroid malignancy. Malignant nodules were significantly larger than benign nodules (2.30 [1.80] cm vs. 1.80 [1.13] cm; p = 0.015). In univariable analysis, TSH, free T4, and multiple ultrasound features were associated with malignancy. In multivariable analysis, nodule size remained the strongest independent predictor of malignancy (adjusted odds ratio [aOR] 1.51; p < 0.001). Hypoechogenicity (aOR 2.07; p = 0.020) and microcalcifications (aOR 1.86; p = 0.047) also remained independently significant, whereas thyroid function parameters were not associated with malignancy after adjustment.
Conclusions
Thyroid nodule size is the strongest independent predictor of malignancy, with select ultrasound features retaining additional predictive value. These findings support incorporating nodule size more prominently into thyroid cancer risk stratification while maintaining key sonographic features.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen 15503, Bahrain.
- King Hamad University Hospital, Muharraq P.O. Box 24343, Bahrain.
- Research Department, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-MUB), Manama P.O. Box 15503, Bahrain.
ORCID-Profile: Osama Zeidan, Talal Sarhan, Zeid Alkhairi, Omar Abusedera, Hasan Kadhem, Alexandra E Butler
Förderung
- RCSI Bahrain
- Royal College of Surgeons in Ireland—Medical University of Bahrain
Zitieren
APA
Zeidan, O., Sarhan, T., Alkhairi, Z., Abusedera, O., Sudani, Q., Kadhem, H., Obaid, J., & Butler, A. E. (2026). Correlation Between Thyroid Nodule Size and Risk of Thyroid Cancer: A Retrospective Cohort Study at a Tertiary Care Center. Diagnostics, 16(10), 1505. https://doi.org/10.3390/diagnostics16101505
Vancouver
Zeidan O, Sarhan T, Alkhairi Z, Abusedera O, Sudani Q, Kadhem H, et al. Correlation Between Thyroid Nodule Size and Risk of Thyroid Cancer: A Retrospective Cohort Study at a Tertiary Care Center. Diagnostics. 2026;16(10):1505. doi:10.3390/diagnostics16101505
BibTeX
@article{Zeidan2026,
author = {Zeidan, Osama and Sarhan, Talal and Alkhairi, Zeid and Abusedera, Omar and Sudani, Qaswar and Kadhem, Hasan and Obaid, Jenan and Butler, Alexandra E},
title = {Correlation Between Thyroid Nodule Size and Risk of Thyroid Cancer: A Retrospective Cohort Study at a Tertiary Care Center},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {10},
pages = {1505},
doi = {10.3390/diagnostics16101505}
}
EUVIMED